Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06388174

Idiopathic Generalized Epilepsy Syndromes

Idiopathic Generalized Epilepsy Syndromes: Clinical Features and Long-term Outcomes

Status
Recruiting
Phase
Study type
Observational
Enrollment
200 (estimated)
Sponsor
Shen Chun-Hong · Academic / Other
Sex
All
Age
4 Years – 40 Years
Healthy volunteers

Summary

The idiopathic generalized epilepsies (IGEs) have historically included the syndromes childhood absence epilepsy (CAE), juvenile absence epilepsy (JAE), juvenile myoclonic epilepsy (JME), and epilepsy with generalized tonic-clonic seizures alone (GTCA). Recognition of the IGEs is important for clinical care, as it informs diagnosis, prevents unnecessary investigation, allows optimal selection of anti-seizure medications (ASMs), and provides prognostic guidance. According to the new ILAE definition in 2022, the study aims to describe the clinical features, electroencephalographic, imaging findings and long-term prognosis.

Detailed description

the Long-term prognosis include the rate of drug-resistent epilepsy, relapse after drug withdrawn, common comorbidities such as mood disorders, attention deficit hyperactivity disorder (ADHD) and learning disabilities.

Conditions

Timeline

Start date
2023-01-01
Primary completion
2026-12-31
Completion
2033-12-31
First posted
2024-04-29
Last updated
2025-08-27

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06388174. Inclusion in this directory is not an endorsement.

Idiopathic Generalized Epilepsy Syndromes (NCT06388174) · Clinical Trials Directory